MeaTech 3D

MeaTech 3D Ltd is engaged in the development of farming methods. It offers an industrial process for growing cultured meat combined with 3D printing technology.

MeaTech 3D Ltd. - American Depositary Shares

MITCHELLS & BUTLERS ORD by Mitchells & Butlers Plc

Mitchells & Butlers

MITCHELLS & BTLRS UNS/ADR by Mitchells & Butlers Plc

Mitani

<h3>Gainers</h3>
<ul>
<li>BurgerFi International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFI#NASDAQ">BFI</a>) stock rose 3.1% to $10.63 during Wednesday's after-market session. BurgerFi International's trading volume hit 290 shares by close, accounting for 0.1% of its average volume over the last 100 days. </li>
<li>China Liberal Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLEU#NASDAQ">CLEU</a>) stock moved upwards by 2.25% to $3.18. Today's trading volume for this security ended up closing at 300 shares, which is 0.01 percent of its average volume over the last 100 days. The company's market cap stands at $39.2 million. </li>
<li>Vinco Ventures (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBIG#NASDAQ">BBIG</a>) stock moved upwards by 2.15% to $4.27. At the close, Vinco Ventures's trading volume reached 65.5K shares. This is 0.64% of its average volume over the last 100 days. The market value of their outstanding shares is at $178.3 million. </li>
<li>Allied Esports (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AESE#NASDAQ">AESE</a>) stock moved upwards by 1.31% to $2.25. Today's trading volume for this security ended up closing at 2.0K shares, which is 0.08 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $88.0 million. </li>
<li>XpresSpa Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XSPA#NASDAQ">XSPA</a>) shares rose 1.28% to $1.58. XpresSpa Group's trading volume hit 647 shares by close, accounting for 0.02% of its average volume over the last 100 days. The company's market cap stands at $166.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Amesite (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMST#NASDAQ">AMST</a>) shares declined by 3.23% to $2.7 during Wednesday's after-market session. Trading volume for this security closed at 12.5K, accounting for 0.94% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $55.5 million. </li>
<li>Express (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXPR#NYSE">EXPR</a>) shares declined by 2.83% to $4.81. At the close, Express's trading volume reached 4.0K shares. This is 0.03% of its average volume over the last 100 days. The market value of their outstanding shares is at $318.9 million. </li>
<li>Kandi Technologies Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KNDI#NASDAQ">KNDI</a>) shares fell 1.64% to $6.03. This security traded at a volume of 206 shares come close, making up 0.01% of its average volume over the last 100 days. The company's market cap stands at $454.5 million. </li>
<li>AYRO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AYRO#NASDAQ">AYRO</a>) stock decreased by 1.64% to $5.41. Trading volume for this security closed at 2.3K, accounting for 0.16% of its average full-day volume over the last 100 days. The company's market cap stands at $190.5 million. </li>
<li>Jiuzi Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JZXN#NASDAQ">JZXN</a>) shares fell 1.62% to $7.91. At the close, Jiuzi Holdings's trading volume reached 4.0K shares. This is 0.11% of its average volume over the last 100 days. </li>
<li>America's Car-Mart (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMT#NASDAQ">CRMT</a>) shares decreased by 1.12% to $143.0. America's Car-Mart's trading volume hit 728 shares by close, accounting for 1.52% of its average volume over the last 100 days. The company's market cap stands at $947.5 million. </li>
</ul>

Movers

AESE

AMST

AYRO

BBIG

CLEU

CRMT

EXPR

JZXN

KNDI

XSPA

11 Consumer Discretionary Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Satsuma Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSA#NASDAQ">STSA</a>) stock increased by 17.17% to $5.8 during Wednesday's after-market session. This security traded at a volume of 1.5 million shares come close, making up 1150.36% of its average volume over the last 100 days. The company's market cap stands at $182.8 million. </li>
<li>Histogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSTO#NASDAQ">HSTO</a>) shares moved upwards by 8.91% to $1.1. Trading volume for this security closed at 1.1 million, accounting for 113.96% of its average full-day volume over the last 100 days. The company's market cap stands at $45.9 million. </li>
<li>Lannett (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LCI#NYSE">LCI</a>) shares moved upwards by 4.98% to $5.05. At the close, Lannett's trading volume reached 238.4K shares. This is 25.32% of its average volume over the last 100 days. The company's market cap stands at $209.3 million. </li>
<li>Synaptogenix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNPX#NASDAQ">SNPX</a>) shares increased by 4.26% to $9.28. Trading volume for this security closed at 4.0K, accounting for 1.51% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $32.5 million. </li>
<li>Star Equity Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRR#NASDAQ">STRR</a>) shares moved upwards by 3.99% to $2.86. Trading volume for this security closed at 7.6K, accounting for 3.84% of its average full-day volume over the last 100 days. </li>
<li>Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) stock rose 3.5% to $59.67. At the close, Prothena Corp's trading volume reached 10.1K shares. This is 2.43% of its average volume over the last 100 days. The market value of their outstanding shares is at $2.6 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>MyMD Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYMD#NASDAQ">MYMD</a>) stock fell 17.46% to $4.73 during Wednesday's after-market session. Today's trading volume for this security ended up closing at 5.5K shares, which is 1.01 percent of its average volume over the last 100 days. </li>
<li>Novan (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NOVN#NASDAQ">NOVN</a>) stock declined by 11.2% to $12.3. Today's trading volume for this security ended up closing at 271.1K shares, which is 3.75 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $186.5 million. </li>
<li>Evaxion Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVAX#NASDAQ">EVAX</a>) stock declined by 7.75% to $6.25. This security traded at a volume of 437 shares come close, making up 0.48% of its average volume over the last 100 days. </li>
<li>Predictive Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POAI#NASDAQ">POAI</a>) shares declined by 3.58% to $1.08. At the close, Predictive Oncology's trading volume reached 54.4K shares. This is 2.11% of its average volume over the last 100 days. The market value of their outstanding shares is at $53.8 million. </li>
<li>Voyager Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYGR#NASDAQ">VYGR</a>) shares decreased by 3.53% to $4.65. This security traded at a volume of 8.4K shares come close, making up 1.47% of its average volume over the last 100 days. The market value of their outstanding shares is at $175.4 million. </li>
<li>Jaguar Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) shares fell 2.86% to $1.7. Jaguar Health's trading volume hit 27.8K shares by close, accounting for 0.25% of its average volume over the last 100 days. The market value of their outstanding shares is at $233.4 million. </li>
</ul>

EVAX

HSTO

JAGX

MyMD Pharmaceuticals, Inc. - Common Stock

MYMD

NOVN

POAI

PRTA

SNPX

STRR

STSA

VYGR

12 Health Care Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Commercial Vehicle Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVGI#NASDAQ">CVGI</a>) shares moved upwards by 3.37% to $11.93 during Wednesday's after-market session. At the close, Commercial Vehicle Group's trading volume reached 10.0K shares. This is 3.54% of its average volume over the last 100 days. The market value of their outstanding shares is at $392.9 million. </li>
<li>Antelope Enterprise Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEHL#NASDAQ">AEHL</a>) shares rose 1.79% to $2.83. This security traded at a volume of 861 shares come close, making up 0.07% of its average volume over the last 100 days. The company's market cap stands at $16.2 million. </li>
<li>Sunrun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) stock rose 1.57% to $48.48. Sunrun's trading volume hit 82.3K shares by close, accounting for 1.37% of its average volume over the last 100 days. The company's market cap stands at $9.8 billion. </li>
<li>ShiftPixy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIXY#NASDAQ">PIXY</a>) stock increased by 1.55% to $2.61. Today's trading volume for this security ended up closing at 301 shares, which is 0.01 percent of its average volume over the last 100 days. The company's market cap stands at $60.6 million. </li>
<li>Staffing 360 Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAF#NASDAQ">STAF</a>) shares moved upwards by 1.38% to $0.61. Today's trading volume for this security ended up closing at 7.1K shares, which is 0.41 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $24.0 million. </li>
<li>Gaucho Group Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINO#NASDAQ">VINO</a>) shares rose 1.12% to $8.07. Gaucho Group Holdings's trading volume hit 2.9 million shares by close, accounting for 1642.98% of its average volume over the last 100 days. The company's market cap stands at $61.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Grindrod Shipping Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRIN#NASDAQ">GRIN</a>) shares declined by 2.52% to $10.85 during Wednesday's after-market session. Today's trading volume for this security ended up closing at 315 shares, which is 0.57 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $208.5 million. </li>
<li>BEST (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEST#NYSE">BEST</a>) stock decreased by 2.31% to $1.27. Trading volume for this security closed at 58.3K, accounting for 1.98% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $493.0 million. </li>
<li>Quad/Graphics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QUAD#NYSE">QUAD</a>) shares decreased by 1.57% to $3.5. Quad/Graphics's trading volume hit 62.9K shares by close, accounting for 18.38% of its average volume over the last 100 days. The market value of their outstanding shares is at $191.3 million. </li>
<li>Globus Maritime (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLBS#NASDAQ">GLBS</a>) shares fell 1.37% to $5.07. Globus Maritime's trading volume hit 1.0K shares by close, accounting for 0.19% of its average volume over the last 100 days. The market value of their outstanding shares is at $53.6 million. </li>
<li>Ocean Power Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPTT#NASDAQ">OPTT</a>) shares fell 1.19% to $2.5. Trading volume for this security closed at 2.3K, accounting for 0.12% of its average full-day volume over the last 100 days. The company's market cap stands at $127.4 million. </li>
<li>EZGO Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZGO#NASDAQ">EZGO</a>) stock declined by 1.02% to $3.91. Trading volume for this security closed at 4.9K, accounting for 1.59% of its average full-day volume over the last 100 days. </li>
</ul>

AEHL

BEST

CVGI

EZGO

GLBS

Grindrod Shipping Holdings Ltd Ordinary Shares

GRIN

OPTT

PIXY

QUAD

STAF

VINO

12 Industrials Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Aware (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWRE#NASDAQ">AWRE</a>) stock increased by 7.59% to $4.11 during Wednesday's after-market session. Trading volume for this security closed at 467, accounting for 1.0% of its average full-day volume over the last 100 days. The company's market cap stands at $88.3 million. </li>
<li>FuboTV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUBO#NYSE">FUBO</a>) shares rose 5.87% to $30.28. FuboTV's trading volume hit 628.6K shares by close, accounting for 4.12% of its average volume over the last 100 days. The company's market cap stands at $4.2 billion. </li>
<li>Qumu (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUMU#NASDAQ">QUMU</a>) shares rose 4.91% to $3.2. Trading volume for this security closed at 4.5K, accounting for 4.95% of its average full-day volume over the last 100 days. The company's market cap stands at $56.2 million. </li>
<li>Bonso Electronics Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNSO#NASDAQ">BNSO</a>) shares moved upwards by 4.84% to $8.22. Bonso Electronics Intl's trading volume hit 763 shares by close, accounting for 0.25% of its average volume over the last 100 days. The company's market cap stands at $39.9 million. </li>
<li>Phunware (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHUN#NASDAQ">PHUN</a>) shares moved upwards by 2.98% to $1.38. Trading volume for this security closed at 805, accounting for 0.01% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $98.8 million. </li>
<li>Cemtrex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CETX#NASDAQ">CETX</a>) stock increased by 2.72% to $1.51. Today's trading volume for this security ended up closing at 500 shares, which is 0.04 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $28.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>ALFI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALF#NASDAQ">ALF</a>) shares fell 3.59% to $6.45 during Wednesday's after-market session. At the close, ALFI's trading volume reached 396.7K shares. This is 3.94% of its average volume over the last 100 days. </li>
<li>Color Star Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCW#NASDAQ">CSCW</a>) shares decreased by 1.79% to $1.1. Trading volume for this security closed at 445, accounting for 0.0% of its average full-day volume over the last 100 days. The company's market cap stands at $99.3 million. </li>
<li>II-VI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IIVI#NASDAQ">IIVI</a>) shares decreased by 1.76% to $67.58. At the close, II-VI's trading volume reached 22.2K shares. This is 1.0% of its average volume over the last 100 days. The market value of their outstanding shares is at $7.0 billion. </li>
<li>Akoustis Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKTS#NASDAQ">AKTS</a>) stock fell 1.71% to $10.4. At the close, Akoustis Technologies's trading volume reached 64.7K shares. This is 10.9% of its average volume over the last 100 days. The market value of their outstanding shares is at $523.8 million. </li>
<li>Inseego (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSG#NASDAQ">INSG</a>) stock decreased by 1.5% to $9.91. Trading volume for this security closed at 5.9K, accounting for 0.29% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $1.0 billion. </li>
<li>WISeKey Intl Hldg (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKEY#NASDAQ">WKEY</a>) stock fell 1.39% to $7.85. Trading volume for this security closed at 597, accounting for 0.01% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $156.6 million. </li>
</ul>

AKTS

AWRE

BNSO

CETX

CSCW

FUBO

IIVI

INSG

PHUN

QUMU

WKEY

12 Information Technology Stocks Moving In Wednesday's After-Market Session

<ul>
<li>Pivotal study conducted in 10 countries in fast changing environment of at least 29 COVID-19 variant strains; original strain almost completely absent</li>
<li>At second interim analysis, statistical success criteria not met. Favorable safety profile confirmed</li>
<li>Initial analyses show trend for age and variant dependent efficacy</li>
<li>Results communicated to EMA, study progressing to final analysis within the next few weeks.</li>
</ul>
T&Uuml;BINGEN, GERMANY &amp; BOSTON, MA / ACCESSWIRE / June 16, 2021 /&nbsp;CureVac N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVAC#NASDAQ">CVAC</a>), a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (&quot;mRNA&quot;), today announced results of the second interim analysis of its international pivotal Phase 2b/3 study in approximatively 40,000 subjects (the HERALD study) of CureVac&#39;s first-generation COVID-19 vaccine candidate, CVnCoV. In the unprecedented context of at least 13 variants circulating within the study population subset assessed at this interim analysis, CVnCoV demonstrated an interim vaccine efficacy of&nbsp;47%&nbsp;against COVID-19 disease of any severity and did not meet prespecified statistical success criteria. Initial analyses suggest age and strain dependent efficacy. Available data were communicated with the European Medicines Agency (EMA). The Data Safety Monitoring Board (DSMB) confirmed a favorable safety profile for CVnCoV. The study is continuing to the final analysis and the totality of the data will be assessed for the most appropriate regulatory pathway.
In total, 134 Covid-19 cases were assessed in this interim analysis. Out of these cases, 124 were sequenced to identify the variant causing the infection. The outcome confirms that only one single case was attributable to the original SARS-CoV-2 virus. More than half of the cases (57%) were caused by Variants of Concern. Most of the remaining cases were caused by other less characterised variants such as Lambda or C.37, first identified in Peru (21%) and B.1.621, first identified in Colombia (7%). In this context, the interim results suggest efficacy in younger participants but did not allow to conclude on efficacy in the age group above 60.
&quot;While we were hoping for a stronger interim outcome, we recognize that demonstrating high efficacy in this unprecedented broad diversity of variants is challenging. As we are continuing toward the final analysis with a minimum of 80 additional cases, the overall vaccine efficacy may change,&quot; said Dr. Franz-Werner Haas, Chief Executive Officer of CureVac. &quot;In addition, the variant-rich environment underlines the importance of developing next-generation vaccines as new virus variants continue to emerge.&quot;
The HERALD study, conducted by Curevac in conjunction with Bayer, enrolled approximately 40,000 participants in ten countries in Latin America and Europe. The second interim analysis included 134 cases, occurring at least two weeks after administration of the second dose. To identify strains causing COVID-19 infections within the trial, sequencing of virus variants has so far been performed on 424 COVID-19 cases, of which 124 fulfilled adjudication criteria and were included in the present efficacy analysis.
CureVac remains committed to COVID-19 vaccine development. Beyond CVnCoV, the company develops in partnership with GSK second-generation COVID-19 vaccine candidates. These candidates are based on new mRNA backbones and include potential variants in multivalent vaccine formats as well as combination vaccines for potential protection against multiple infectious diseases in one vaccine. Preclinical data from the first vaccine candidate, CV2CoV, has recently been accepted for publication in Nature Communications. CureVac and GSK expect to progress the second-generation vaccine candidate into clinical testing in the&nbsp;third quarter&nbsp;of 2021, with the goal of introducing the vaccine in 2022, subject to regulatory approval.
CureVac will also host a webcast and conference call on Thursday, June 17, 2021 at 2:00 p.m. CET / 8:00 a.m. EST. The live conference call dial-in details and webcast link can be accessed via the Investor Relations section of the CureVac website at&nbsp;<a href="https://www.curevac.com/en/newsroom/events/">https://www.curevac.com/en/newsroom/events/</a>.
Corresponding presentation slides will be posted shortly before the start of the webcast. A replay will be made available on this website after the event.
About CVnCoV 
CureVac began development of mRNA-based COVID-19 vaccine candidates in January 2020. The vaccine candidate chosen for first clinical development, CVnCoV, is an optimized, non-chemically modified mRNA, encoding the prefusion stabilized full-length spike protein of the SARS-CoV-2 virus, and formulated within Lipid Nanoparticles (LNPs). Phase 1 and 2a clinical trials of CVnCoV began in June and September 2020, respectively. Phase 1 interim data reported in November 2020 showed that CVnCoV was generally well tolerated across all tested doses and induced strong antibody responses in addition to first indication of T cell activation. The quality of the immune response was comparable to recovered COVID-19 patients, closely mimicking the immune response after natural COVID-19 infection. A pivotal Phase 2b/3, the HERALD study, with a 12&micro;g dose of CVnCoV was initiated in December 2020. In February 2021, CureVac initiated a rolling submission with the European Medicines Agency (EMA) for CVnCoV.
About CureVac 
CureVac is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing and optimizing the versatile biological molecule for medical purposes. The principle of CureVac&#39;s proprietary technology is the use of non-chemically modified mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases. Based on its proprietary technology, the Company has built a deep clinical pipeline across the areas of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases. CureVac had its initial public offering on the New York Nasdaq in August 2020. It is headquartered in T&uuml;bingen, Germany, and employs more than 700 people at its sites in T&uuml;bingen, Frankfurt, and Boston, USA. Further information can be found at&nbsp;<a href="https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&amp;url=5b5564410af929f2780099de29db56d3&amp;application_id=1208905&amp;site_id=issuer_direct&amp;application_name=news">www.curevac.com</a>.
CureVac Investor Relations Contact 
Dr. Sarah Fakih, Vice President Corporate Communications and Investor Relations 
CureVac, T&uuml;bingen, Germany 
T: +49 7071 9883-1298 
M: +49 160 90 496949 
<a href="mailto:sarah.fakih@curevac.com">sarah.fakih@curevac.com</a>
CureVac Media Contact 
Anna Kamilli, Manager Communications 
CureVac, T&uuml;bingen, Germany 
T: +49 7071 9883-1684 
<a href="mailto:anna.kamilli@curevac.com">anna.kamilli@curevac.com</a>
Bettina J&ouml;dicke-Braas, Manager Communications 
CureVac, T&uuml;bingen, Germany 
T: 49 7071 9883-1087 
<a href="mailto:bettina.joedicke-braas@curevac.com">bettina.joedicke-braas@curevac.com</a>
Forward-Looking Statements 
This press release contains statements that constitute &quot;forward looking statements&quot; as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the opinions, expectations, beliefs, plans, objectives, assumptions or projections of CureVac N.V. and/or its wholly owned subsidiaries CureVac AG, CureVac Real Estate GmbH, CureVac Inc and CureVac Swiss AG. (the &quot;company&quot;) regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of the potential efficacy of the company&#39;s vaccine and treatment candidates and the company&#39;s strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as &quot;anticipate,&quot; &quot;intend,&quot; &quot;believe,&quot; &quot;estimate,&quot; &quot;plan,&quot; &quot;seek,&quot; &quot;project,&quot; or &quot;expect,&quot; &quot;may,&quot; &quot;will,&quot; &quot;would,&quot; &quot;could,&quot; &quot;potential,&quot; &quot;intend,&quot; or &quot;should,&quot; the negative of these terms or similar expressions. Forward-looking statements are based on management&#39;s current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of the company&#39;s performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and collaboration partners, ability to commercialize products, ability to manufacture any products, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in the company&#39;s industry, the effects of the COVID-19 pandemic on the company&#39;s business and results of operations, ability to manage growth, reliance on key personnel, reliance on intellectual property protection, ability to provide for patient safety, and fluctuations of operating results due to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company&#39;s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this press release are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.
For further information, please reference the company&#39;s reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at&nbsp;<a href="https://www.sedar.com/">www.sec.gov</a>.
SOURCE:&nbsp;CureVac
View source version on accesswire.com: 
<a href="https://www.accesswire.com/652038/CureVac-Provides-Update-on-Phase-2b3-Trial-of-First-Generation-COVID-19-Vaccine-Candidate-CVnCoV">https://www.accesswire.com/652038/CureVac-Provides-Update-on-Phase-2b3-Trial-of-First-Generation-COVID-19-Vaccine-Candidate-CVnCoV</a>
<img src="https://www.accesswire.com/img.ashx?id=652038" style="height:0px; width:0px" />

News

CVAC

CureVac Issues PR Confirming Earlier News Co's COVID-19 Vaccine Demonstrated An Interim Vaccine Efficacy Of 47% Against COVID-19 Disease Of Any Severity And Did Not Meet Prespecified Statistical Success Criteria

<a href="https://www.bloomberg.com/news/articles/2021-04-09/musk-deletes-tweet-speculating-on-curevac-s-vaccine-approval?sref=wSbDKtLK" target="_blank">https://www.bloomberg.com/news/articles/2021-04-09/musk-deletes-tweet-speculating-on-curevac-s-vaccine-approval?sref=wSbDKtLK</a>

Contracts

TSLA

Watching Tesla Shares; Traders Circulate April Bloomberg Report Titled 'Musk Deletes Tweet Speculating on CureVac's Vaccine Approval'

Legal

WKHS

Workhorse Files Formal Complaint Regarding USPS NGDV Contract; Says Unable To Provide Any Further Information With Respect To Matter; Says Will Provide Updates When Appropriate And As Permitted Under Its Non-Disclosure Agreement As Part Of NGDV Program

National Expungement Works (N.E.W.),&nbsp;formerly known as National Expungement Week,&nbsp;an organization that has helped shape the national conversation around expungement and legal relief impacting millions, will broach this thought-provoking topic and many others as part of its third-annual observance of Juneteenth.
The event series kicked off Sunday, June 13th at 7:30 pm ET, with a &ldquo;Who&rsquo;s Invited to the Cookout?&rdquo; online webinar.
The series will culminate with in-person&nbsp;socially distant events on Saturday, June 19, 2021 in multiple cities across the country: Chicago, IL; Detroit, MI; Los Angeles, CA; and Philadelphia, PA.
The 2.5-hour webinar will feature keynote speakers, educational break-out sessions&nbsp;and giveaways. &ldquo;Who&rsquo;s invited to the cookout?&rdquo; is sponsored in part by Green Thumb Industries (OTC: <a class="ticker" href="https://www.benzinga.com/stock/gtbif#OTC">GTBIF</a>).
To participate in N.E.W.&rsquo;s Juneteenth event, please visit <a href="http://bit.ly/NEWJuneteenth.">http://bit.ly/NEWJuneteenth.&nbsp;</a>
&ldquo;This year&rsquo;s webinar takes place around a virtual dinner table with a family-style conversation featuring justice-impacted voices, legal perspectives on legislation and its compounded impact on the Black community, and healing practices for coping, surviving and thriving within this system of injustice,&rdquo; said&nbsp;Jessica Jackson, Director of Operations for N.E.W. &ldquo;These are the conversations that are required for both BIPOC and the global communities to honor the legacy Juneteenth while leveraging the value of impact that resonates today. Trust and believe every speaker will have a full plate, a selected track on our playlist!&rdquo;&nbsp;&nbsp;
Encuentra nuestro contenido en Espa&ntilde;ol en El Planteo:
<ul>
<li><a href="https://elplanteo.com/cultivo-de-marihuana-en-interior/">Introducci&oacute;n al Cultivo de Marihuana en Interior (o Indoor)</a></li>
<li><a href="https://elplanteo.com/la-historia-de-yvy-la-empresa-uruguay-de-cannabis-medicinal/">La Historia de YVY, la Exitosa Empresa Uruguaya de Cannabis Medicinal</a></li>
</ul>

Cannabis

Markets

GTBIF

Cannabis Organization National Expungement Works To Host Juneteenth Events This Month

<a href="https://www.curevac.com/en/2021/06/16/curevac-provides-update-on-phase-2b-3-trial-of-first-generation-covid-19-vaccine-candidate-cvncov/" target="_blank">https://www.curevac.com/en/2021/06/16/curevac-provides-update-on-phase-2b-3-trial-of-first-generation-covid-19-vaccine-candidate-cvncov/</a>

CureVac Says COVID-19 Vaccine Demonstrated An Interim Vaccine Efficacy Of 47% Against COVID-19 Disease Of Any Severity And Did Not Meet Prespecified Statistical Success Criteria

In a <a href="https://www.youtube.com/watch?v=xCXbftjfEjI" style="color:#0563c1; text-decoration:underline">video</a> examining the &ldquo;SEC Danger rating&rdquo; of the top five cryptocurrencies by market cap, attorney Jeremy Hogan said that both Tether and Binance Coin might be the next targets of an SEC lawsuit.
What Happened:&nbsp;Hogan, who is a partner at Hogan &amp; Hogan, gained popularity after posting brief videos about his opinion on the legal proceedings unfolding between XRP issuer Ripple Labs and the U.S. Securities and Exchange Commission.
Based on the arguments made by the SEC in its legal case against XRP, Hogan named controversial stablecoin Tether as a coin that might be liable to an SEC lawsuit.
The attorney gave Tether a 9/10 on his danger rating scale, citing the company&rsquo;s recent $18.5 million settlement with the New York Attorney General (NYAG).
Tether&rsquo;s parent company Bitfinex paid the fine to end the investigation into an alleged cover-up of an $850 million loss.
Hogan also named Binance Coin (BNB) as another token that might face legal action from the SEC, giving the coin a danger rating of 8.5/10.
Analyzing BNB under the Howey test, Hogan pointed out that Binance carried out an ICO or Initial Coin Offering back in 2017.
&ldquo;Now this is the exact thing that Chairman Clayton and new SEC Chairman Gensler have basically said is an investment contract,&rdquo; he said.
Read also:&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/21/05/21316464/gary-gensler-says-crypto-is-slipping-through-gaps-proposes-crypto-exchange-regulation">Gary Gensler Says Crypto Is Slipping Through Gaps, Proposes Crypto Exchange Regulation</a>
&ldquo;To make matters worse, the control of the Binance coin is very centralized. In fact, in order to maintain the value of the coin, Binance buys back and burns coins every quarter&nbsp;and even said in its whitepaper that the purpose of doing so is to keep the coin scarce and valuable.&rdquo;
Last month, SEC Chairman Gary Gensler went on <a href="https://www.benzinga.com/markets/cryptocurrency/21/05/21014629/new-sec-chairman-gary-gensler-confirms-a-lot-of-cryptocurrencies-are-indeed-securities-pav" style="color:#0563c1; text-decoration:underline">record</a> to state that &ldquo;a lot of crypto tokens are indeed securities&rdquo; and plans to bring them back into the rules.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Fintech news covering the emerging Financial Technology services sector

Fintech

Government

$BTC

$ETH

Tether (USDT) And Binance Coin (BNB) Are Likely Targets For SEC Lawsuit, Says Crypto Legal Expert

CureVac Provides Update On Phase 2b/3 Trial Of First-Generation COVID-19 Vaccine Candidate, CVnCoV

On June 17&nbsp;at 12 p.m.&nbsp;ET, Shiba Inu (CRYPTO: SHIB) will begin trading on the Coinbase Pro exchange.
How to buy: <a href="http://www.benzinga.com/go/coinbase">Coinbase Pro</a> requires users to first purchase USDC, which can then be spent on SHIB and other supported cryptocurrencies. Alternatively, Coinbase allows you to send your assets from the Coinbase wallet to your Coinbase Pro wallet off-chain for free. If you have BTC or ETH on your Coinbase, you can send these assets to your Coinbase Pro wallet for free, and enter SHIBA through the SHIBA-BTC or the SHIBA-ETH trading pairs.
Shiba Inu is a doggy-themed cryptocurrency that aims to take the hype behind Dogecoin to a new level. The platform differentiates itself from Dogecoin with plans to launch its own decentralized exchange and NFT system.
While Dogecoin runs on its own blockchain, Shiba Inu is built on the Ethereum blockchain. Shiba Inu benefits from Ethereum&rsquo;s decentralization and security but suffers from Ethereum&rsquo;s high transaction fees.
See also: <a href="https://www.benzinga.com/money/how-to-buy-dogecoin-doge/">How to Buy Dogecoin</a>
Shiba Inu saw an incredible spike in May of 2021 followed by a sharp decline along with the rest of the market. While it was previously only available to US customers on crypto.com&rsquo;s exchange and non-KYC decentralized exchanges like Uniswap and Sushiswap, Shiba Inu is soon to be listed on one of the biggest centralized crypto exchanges worldwide: Coinbase Pro.
Coinbase Pro is a separate app from Coinbase and offers some unique features such as lower fees and limit orders. If you are already a Coinbase user, you can download the app and sign up using your existing Coinbase account.
Currently, you can deposit SHIB from your MetaMask or <a href="http://www.benzinga.com/go/crypto-com">Crypto.com</a> wallets onto Coinbase Pro. If you want to sell SHIB to the new Coinbase Pro buyers when trading begins, you&rsquo;ll want to deposit the funds sooner than later.

How To Buy Shiba Inu On Coinbase Pro

Life has a way of&nbsp;creating stranger-than-fiction scenarios&nbsp;like&nbsp;this one:&nbsp;first, you get cancer. Then&nbsp;you become strong enough to fight it off and survive. Then, after all that, you decide to be noble and humane and share the medical insights you gained while struggling with your health issues and you end up facing a death sentence...this time not from cancer, but a firing squad.
Talk about irony.&nbsp;
This is the&nbsp;story of Amiruddin Nadarajan Abdullah, 62, better known as Dr. Ganja or Dr.G.
After being&nbsp;diagnosed with a painful spinal cord tumor that caused him to lose a kidney, Dr. Ganja, who was struggling with&nbsp;chronic pain and chemo-related fatigue, decided to seek&nbsp;out alternative treatments that eventually led him to medical cannabis in the form of hemp seed oil. It worked wonders for him until he was arrested and charged for distributing chocolates and brownies made with hemp seed oil.&nbsp;Dr. Ganja is actually not an MD. He earned that nickname&nbsp;because of his habit of&nbsp;inviting people suffering from cancer and other ailments into his home and sharing his hemp oil medicine with them.
Despite a United Nations decision last year to&nbsp;<a href="https://news.un.org/en/story/2020/12/1079132">recognize the medicinal properties of cannabis</a>, many advocates hoped countries around the world would catch up with evolving attitudes towards the plant. Some did. Malayasia was not one of&nbsp;them. The southeast Asian country continues to&nbsp;have&nbsp;the harshest cannabis laws in the world, including the&nbsp;death penalty for convicted drug traffickers.
Dr. G, who served in the Malaysian army for 22&nbsp;years,&nbsp;was arrested in 2017 and charged with 36 offenses under Malaysia&rsquo;s Dangerous Drugs Act.
&ldquo;He isn&rsquo;t a drug dealer or some drug lord,&rdquo; his daughter Siti&nbsp;told <a href="https://www.vice.com/en/article/g5bexx/dr-ganja-death-penalty-weed-medical-marijuana">VICE World News</a>.
Malaysian Princess And The Last Prisoner Project Join Forces To Help Dr. Ganja
The Malaysian Princess Tengku Chanela Jamidah&nbsp;is collaborating with the Last Prisoner Project&nbsp;(LPP ) to support Dr. Ganja&#39;s appeal,&nbsp;<a href="https://www.forbes.com/sites/lindseybartlett/2021/06/15/malaysian-princess-aims-to-free-cancer-survivor-dr-ganja-from-possible-death-sentence-over-cannabis/?sh=4593a975117f" target="_blank">reported Forbes</a>. Together they have launched an event to raise funds for his cause.
The&nbsp;fundraiser is the LPP&#39;s first&nbsp;international cannabis project, but they&#39;re all in.&nbsp;
&ldquo;Last Prisoner Project holds a vision of freedom for every last cannabis prisoner around the globe,&rdquo; said Mary Bailey, managing director of LPP,&nbsp;a non-profit involved in criminal justice reform.
Princess Jamidah said Malaysia should allow cannabis as an inherent human right. As a&nbsp;well-known figure in the fashion, beauty&nbsp;and entertainment sectors, she has used her broad platform for the last two years to promote cannabis legalization. She&nbsp;is also the official patron of the Malaysian cannabis advocacy group MASA.
<h3>&lsquo;I Will Not Stop Until He Is Free&rsquo;&nbsp;</h3>
In an interview with Forbes, the Princess explained that Malaysians should be reminded that cannabis and hemp have been used by their ancestors for hundreds of years.
&ldquo;I am aware that there are many within the family and outside of the family who oppose what I do. This is not what I fear. I fear living a life that is not in honor of my authenticity and truth, I believe the plant is extremely intelligent and she is our teacher and I would rather live my life in acknowledgment of that truth than live a life deprived of my soul&rsquo;s path and mission,&rdquo; Jamidah said.
The princess emphasized the larger picture and the many patients in need of medical marijuana.&nbsp;
&ldquo;We must consider the epileptic child, the cancer patient, Alzheimer&#39;s and Parkinson&rsquo;s patients that are faced with pain, suffering and risk their lives every day deprived of this medicine that has been proven to heal. What are my risks compared to their courage and survival?&rdquo;
The princess is as adamant about freeing Dr. G as she is about the cannabis plant.
&ldquo;Let my voice and activism be a vessel for Dr. G as we believe in the same truths, I will not stop until he is free,&rdquo; the Princess said.
Those who wish may contribute to&nbsp;<a href="https://www.simplygiving.com/PersonalFundraising/supportsitianddrg" target="_blank">Dr. G&rsquo;s Crowdfunding campaign</a>. All&nbsp;proceeds will be used to support his death sentence appeal and, hopefully, his&nbsp;release.
Photo by <a href="https://unsplash.com/@nicolafioravanti?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText">Nicola Fioravanti</a> on <a href="https://unsplash.com/s/photos/heart?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText">Unsplash</a>

Malaysian Princess Struggles To Free Cancer Survivor Dr. Ganja Who Faces Possible Death Sentence Over Medical Cannabis

WLTW

U.S. Justice Department Says It Sues To Block Aon's Acquisition Of Willis Towers Watson

Guidance

SNCR

Synchronoss Reaffirms Fiscal Year 2021 Guidance; Co. Previously FY21 Sales $275M-$285M

Management

Synchronoss Announces CFO David Clark To Step Down; Co. Searching For Successor

On <a href="https://www.cnbc.com/video/2021/06/16/your-question-your-trade-askhalftime.html">CNBC&#39;s &quot;Fast Money Halftime Report,&quot;</a> Joe Terranova said it&#39;s a good time to add Microsoft Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/msft#NASDAQ">MSFT</a>) to a portfolio. It&#39;s well positioned to grab market share in the cloud.
Jenny Harrington said if you prefer owning individual names, you should buy Medtronic PLC (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mdt#NYSE">MDT</a>) and if you want diversification, you should own iShares US Medical Devices ETF (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ihi#NYSE">IHI</a>). You are going to make money in either case, she said.
Stephen Weiss said Jumia Technologies AG - ADR (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/jmia#NYSE">JMIA</a>) and Vuzix Corp (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vuzi#NASDAQ">VUZI</a>) stand an equal chance to pay off in five years. They&#39;re speculative so he would only put speculative money in them.
Jason Snipe said Paypal Holdings Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pypl#NASDAQ">PYPL</a>) is a hold at this point.

Media

iShares Dow Jones US Medical Devices Index Fund

JMIA

MSFT

PYPL

VUZI

'Halftime Report' Traders Share Their Thoughts On Microsoft, PayPal And More

Ethereum Classic (CRYPTO: $ETC) is the old version of Ethereum (CRYPTO: $ETH) before the company switched to the proof of stake platform.
With the recent dip in the entirety of the crypto market, Ethereum Classic lost some gains, but has since made some of it back. Now, Ethereum Classic could find support near a previous resistance level and possibly start moving higher.
Ethereum Classic was down 3.33% at $56.25&nbsp;at last check Wednesday afternoon at publication.
<img alt="etcdaily6-16-21.png" src="https://www.benzinga.com/files/u285825/etcdaily6-16-21.png" style="height:400px; width:640px" />
<h3>Ethereum Classic Daily Chart Analysis:</h3>
<ul>
<li>
Ethereum Classic was trading within a pennant pattern and has not seen a large move yet. If the volume and large move don&rsquo;t come, the crypto may fall to an old resistance level.
</li>
<li>The crypto is trading below the 50-day moving average (green), but above the 200-day moving average (blue). This indicates the crypto is likely in a period of consolidation.</li>
<li>The 50-day moving average may hold as an area of resistance, while support may be found near the 200-day moving average.</li>
</ul>
<h3>Key Levels To Watch:</h3>
The pennant pattern that formed has not seen a large move in either direction as of yet.
<ul>
<li>If the volume does not come into Ethereum Classic, then the crypto may fade until it reaches an old resistance.</li>
<li>Following the breakout, the $40 level&nbsp;previously held as resistance. Later, the crypto found support near this level multiple times&nbsp;and may again in the future.</li>
</ul>
<h3>What&rsquo;s Next?</h3>
Bullish technical traders would like to see Ethereum Classic get some volume and see a push higher. The breakout of the pennant pattern could still happen although the stock is not trading within the pennant pattern.
Bearish technical traders would like to see Ethereum Classic see a strong push down. It could also see a break of the pennant pattern to the downside. If Ethereum Classic falls more, bears would like to see it break below the $40 level and then hold it as resistance once again for further downward moves.
(Photo: Ethereum Classic)
&nbsp;
&nbsp;

Long Ideas

Short Ideas

Technicals

Trading Ideas

Here's Why Ethereum Classic Could Make A Large Move In Either Direction

STRM

Streamline Health Solutions Reports Received Notice From Western Alliance Bank That US Small Business Admin. Approved Forgiveness Of Paycheck Protection Program Loan

<h2>EUR/USD Current Price: 1.2010</h2>
<ul>
<li>The US Federal Reserve upwardly revised its growth and inflation forecasts.</li>
<li>US policymakers moved forward rate hikes expectations, according to the dot-plot.</li>
<li>EUR/USD is bearish despite oversold, further declines likely once below 1.1985.</li>
</ul>
<a href="https://www.fxstreet.com/rates-charts/chart-interactive?asset=eurusd&amp;config=https://editorial.blob.core.windows.net:443/chartconfigs/valeria/eurusdValeriaBednarik4h.json" target="_blank"><img alt="" src="https://editorial.fxstreet.com/miscelaneous/EUR_USD-637594707667754927.png" style="height:323px; width:640px" /></a>
The EUR/USD pair spent the day hovering in the 1.2110/20 price zone, unable to move ahead of the US Federal Reserve&rsquo;s decision. The central bank has left the interest rate and its easing programs unchanged as widely anticipated, but there was a clear hawkish shift in the economic projections. Policymakers see US GDP growing 7.0% in 2021 from a previous 6.5%and 3.3% in 2022. On inflation, PCE figure is now seen at 3.4% for this year and at 2.1% for the next one.
Policymakers reiterated that&nbsp;<a href="https://www.fxstreet.com/rates-charts/rates">rates</a>&nbsp;will remain unchanged &quot;until labor market conditions have reached levels consistent with the Committee&#39;s assessments of maximum employment and inflation has risen to 2 per cent and is on track to moderately exceed 2 per cent for some time.&quot; However, the dot plot showed that 7 Fed officials expect hikes in 2022, while 13 expect hikes in 2023. Chief&nbsp;<a href="https://www.fxstreet.com/macroeconomics/central-banks/fed">Jerome Powell</a>&nbsp;said that the revisions came as inflation accelerated faster and could be more persistent than expected.
The EU macroeconomic calendar had nothing to offer, while the US published May Building Permits, down 3% in the month, and Housing Starts, which were up by 3.6%. On Thursday, the Union will publish May inflation figures, with the annual Consumer Price Index foreseen at 2%. &nbsp;The US will publish the June Philadelphia Fed Manufacturing Survey and Initial&nbsp;<a href="https://www.fxstreet.com/economic-calendar/united-states">Jobless Claims</a>&nbsp;for the week ended June 11, foreseen at 359K.
<h3>EUR/USD short-term technical outlook</h3>
The EUR/USD pair plummeted with the headline, currently trading near a daily low of 1.20, oversold but bearish in the near-term. After shedding over 100 pips with the Fed, the 4-hour chart shows that technical indicators keep heading firmly lower within negative levels. The pair is sharply below a bearish 20 SMA after spending the last two days trying to recover above it. May&rsquo;s monthly low at 1.1985 is the immediate support level. The pair could recover some ground amid oversold conditions, yet as long as it trades below 1.2050, bears will retain control.
Support levels: 1.1985 1.1940 1.1890
Resistance levels: 1.2050 1.2095 1.2140
Image Sourced from Pixabay

Eurozone

Global

General

EUR/USD Is Bearish Despite Oversold, Further Declines Likely Once Below 1.1985

This week&#39;s schedule consists of five IPOs and one direct listing.

<h4>E-commerce</h4>

South Korea&#39;s answer to Amazon (NASDAQ:<a class="ticker" href="/stock/AMZN#NASDAQ">AMZN</a>), the giant Coupang (NYSE:<a class="ticker" href="/stock/CPNG#NYSE">CPNG</a>) plans to raise $3.4 billion at a $51.0 billion market cap. A leading player in its market, the company nearly doubled revenue in 2020 and has expanded its margins. But, much like Amazon for many years, it remains unprofitable.

The company&#39;s significant investments in fulfillment will continue to weigh on cash flow in the near term. Its public debut has been overshadowed by series of injuries and deaths of its workers as eight employees have reportedly died over the past year due to overwork. Although South Korea has strong labor laws for full-time workers, including a maximum 52-hour work week, compulsory one-hour breaks during an eight-hour shift, and mandatory medical insurance for work-related injuries, these laws do not apply to temporary workers without contracts, and unions say there are many loopholes that companies such as Coupang are exploiting. Moreover, Financial Times reported its warehouse workers claim that the workload is much heavier compared to the company&#39;s rivals.

<h4>Online gaming</h4>

Online gaming platform Roblox (NYSE:<a class="ticker" href="/stock/RBLX#NYSE">RBLX</a>) will be 2021&#39;s first direct listing. With an estimated market value at listing exceeding $29 billion, the company is still unprofitable with strong free cash flow. Its growth has been accelerated by the pandemic, although all of its revenues depend only on 1% of players. The platform for user-generated games is a universe of interconnected worlds created by CEO Dave Baszucki and the late Erik Cassel who played around with physics in a virtual world. They ended up coded a platform where kids and adults could interact in 3D simulated virtual environments that resembles virtual Legos. Some of its games have been played billions of times.

<h4>Pool equipment</h4>

Pool equipment supplier Hayward Holdings (NYSE:<a class="ticker" href="/stock/HAYW#NYSE">HAYW</a>) plans to raise $725 million at its New York public debut at a $4.4 billion market cap. The company is a global industry leader with a broad portfolio that holds an estimated 30% share of the North American residential pool market with its largest customer accounting for 30% of its 2020 sales, and its top five customers making 43% of its sales.

<h4>Craft</h4>

Fabric and crafts retailer JOANN (NASDAQ:<a class="ticker" href="/stock/JOAN#NASDAQ">JOAN</a>) plans to raise $175 million but Barrons estimates it could raise as much as $186 million. The company operates a nationwide network of 855 sewing, fabrics, and arts and crafts retail stores, leveraged by an online digital platform as it sells fabric, sewing supplies, and paints and brushes, many of which became more needed than ever for mask-making. It is the nation&#39;s leader in sewing as it controls approximately one-third of the market. The company is expected to make its NASDAQ debut on March 11th.

<h4>From after-school tutoring to an education group</h4>

The largest operator of private high schools in Western China and the third largest operator in China by student enrollment as of December 31, 2019, First High-School Education Group (NYSE:<a class="ticker" href="/stock/FHS#NYSE">FHS</a>) plans to raise $75 million at a $289 million market cap. Although it was originally established to provide after-school tutoring services, the company now owns 19 schools in its developing network.

<h4>Meat steak technology</h4>

Israeli tech company that develops cultured meat tech products, MeaTech 3D (NASDAQ:<a class="ticker" href="/stock/MITC#NASDAQ">MITC</a>) plans to raise $25 million at a $175 million market cap. This is a technology company focused on developing and out-licensing its proprietary 3D printing technology, biotechnology processes and customizable manufacturing processes to food companies that manufacture proteins without animal slaughter. In the third quarter of fiscal 2020, the company successfully printed meat tissue from stem cells as it delivered a&nbsp;thin, slaughter-free steak, but it has not generated any revenues and this will continue to be the case in the near future.

This article is not a press release and is contributed by IAMNewswire. It should not be construed as investment advice at any time please read the full <a href="https://iamnewswire.com/disclaimer-disclosure/">disclosure</a>. IAM Newswire does not hold any position in the mentioned companies. Press Releases &ndash; If you are looking for full Press release distribution contact: <a href="mailto:press@iamnewswire.com">press@iamnewswire.com</a> Contributors &ndash; IAM Newswire accepts pitches. If you&#39;re interested in becoming an IAM journalist contact: <a href="mailto:contributors@iamnewswire.com">contributors@iamnewswire.com</a>

The post <a href="https://iamnewswire.com/five-ipo-week-ahead/" rel="nofollow">Five IPO Week Ahead</a> appeared first on <a href="https://iamnewswire.com" rel="nofollow">IAM Newswire</a>.

IPOs

Five IPOs In The Week Ahead

MeaTech Shares Will Open For Quote At 9:50 a.m. EST; Expected To Open For Trade After 10 a.m. EST; IPO Priced At $10.30/ADS

MeaTech Shares Open For Trade At $9.47; IPO Priced At $10.30/ADS

<h3>Gainers</h3>

<ul>
	<li>Acer Therapeutics Inc. (NASDAQ:<a class="ticker" href="/stock/ACER#NASDAQ">ACER</a>) shares rose 87.1% to $6.38 in pre-market trading. Acer Therapeutics, earlier during the month, reported a narrower quarterly loss.</li>
	<li>Rubius Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/RUBY#NASDAQ">RUBY</a>) rose 35.2% to $22.22 in pre-market trading. Rubius Therapeutics, last week, highlighted it will present trial results from ongoing Phase 1/2 trial of RTX-240 in advanced solid tumors at the American Association Of Cancer Research Meeting Apr. 10-15.</li>
	<li>ADiTx Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/ADTX#NASDAQ">ADTX</a>) rose 32.6% to $4.39 in pre-market trading after gaining more than 10% on Friday.</li>
	<li>GenMark Diagnostics, Inc.. (NASDAQ:<a class="ticker" href="/stock/GNMK#NASDAQ">GNMK</a>) rose 28.7% to $23.80 in pre-market trading. Roche Holding AG announced plans to acquire GenMark Diagnostics for $24.05 per share in cash, or about $1.8 billion, on a fully diluted basis.</li>
	<li>Lixte Biotechnology Holdings, Inc. (NASDAQ:<a class="ticker" href="/stock/LIXT#NASDAQ">LIXT</a>) shares rose 25.2% to $5.47 in pre-market trading after climbing 14% on Friday. Lixte Biotech, earlier during the month, announced a $4.19 million registered direct offering.</li>
	<li>Luokung Technology Corp. (NASDAQ:<a class="ticker" href="/stock/LKCO#NASDAQ">LKCO</a>) shares rose 18.9% to $1.26 in pre-market trading. Luokung Technology, last week, reported Nasdaq withdrawal of delisting notice.</li>
	<li>Pyxis Tankers Inc. (NASDAQ:<a class="ticker" href="/stock/PXS#NASDAQ">PXS</a>) rose 17% to $1.79 in pre-market trading after dropping around 7% on Friday.</li>
	<li>Ebang International Holdings Inc. (NASDAQ:<a class="ticker" href="/stock/EBON#NASDAQ">EBON</a>) rose 16.8% to $12.15 in pre-market trading. Ebang International shares jumped over 35% on Friday following the company&rsquo;s announcement of a cryptocurrency exchange. The cryptocurrency exchange will begin beta testing March 15 and launch by the end of the month, according to the company.</li>
	<li>BioCryst Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/BCRX#NASDAQ">BCRX</a>) rose 14.6% to $14.49 in pre-market trading. BioCryst, last week, said French National Agency for Medicines and Health Products Safety has granted temporary authorization for use for Berotralstat.</li>
	<li>LAIX Inc. (NYSE:<a class="ticker" href="/stock/LAIX#NYSE">LAIX</a>) rose 14.1% to $3.48 in pre-market trading.</li>
	<li>EuroDry Ltd. (NASDAQ:<a class="ticker" href="/stock/EDRY#NASDAQ">EDRY</a>) rose 12.7% to $8.99 in pre-market trading.</li>
	<li>Nxt-ID, Inc. (NASDAQ:<a class="ticker" href="/stock/NXTD#NASDAQ">NXTD</a>) rose 10.6% to $1.78 in pre-market trading after declining 7% on Friday.</li>
	<li>ZW Data Action Technologies Inc. (NASDAQ:<a class="ticker" href="/stock/CNET#NASDAQ">CNET</a>) rose 9.9% to $3.45 in pre-market trading after gaining over 5% on Friday.</li>
	<li>Canaan Inc. (NASDAQ:<a class="ticker" href="/stock/CAN#NASDAQ">CAN</a>) rose 9.5% to $37.91 in pre-market trading after declining around 5% on Friday.</li>
	<li>The9 Limited (NASDAQ:<a class="ticker" href="/stock/NCTY#NASDAQ">NCTY</a>) rose 9.2% to $66.21 in pre-market trading. The9, last week, signed three MOUs to acquire additional Bitcoin mining machines.</li>
	<li>Westwater Resources, Inc. (NASDAQ:<a class="ticker" href="/stock/WWR#NASDAQ">WWR</a>) rose 9.1% to $6.83 in pre-market trading. The company said it will change its listing from the Nasdaq Capital Market to the NYSE American stock exchange on March 19, 2021.</li>
	<li>RiceBran Technologies (NASDAQ:<a class="ticker" href="/stock/RIBT#NASDAQ">RIBT</a>) rose 8.7% to $1.13 in pre-market trading.</li>
	<li>Marathon Digital Holdings, Inc. (NASDAQ:<a class="ticker" href="/stock/MARA#NASDAQ">MARA</a>) rose 8.7% to $44.25 in pre-market trading.</li>
	<li>MeaTech 3D Ltd. (NASDAQ:<a class="ticker" href="/stock/MITC#NASDAQ">MITC</a>) shares rose 8.6% to $10.86 in pre-market trading. The company, on Friday, priced its IPO at $10.30 per ADS.</li>
	<li>Denison Mines Corp. (NYSE:<a class="ticker" href="/stock/DNN#NYSE">DNN</a>) shares rose 7.9% to $1.23 in pre-market trading after climbing around 10% on Friday.</li>
	<li>Meten EdtechX Education Group Ltd. (NASDAQ:<a class="ticker" href="/stock/METX#NASDAQ">METX</a>) rose 7.8% to $2.90 in pre-market trading. Meten EdtechX Education shares gained around 9% on Friday after the company announced its strategy to make full use of blockchain technology in the education industry.</li>
	<li>Riot Blockchain, Inc. (NASDAQ:<a class="ticker" href="/stock/RIOT#NASDAQ">RIOT</a>) rose 7% to $67.17 in pre-market trading.</li>
</ul>

 
Find out what&#39;s going on in today&#39;s market and bring any questions you have to <a href="http://premarket.benzinga.com/pre-market-show/">Benzinga&#39;s PreMarket Prep</a>.

<a href="https://www.benzinga.com/investing/best-penny-stocks/">Check out these big penny stock gainers and losers</a>

<h3>Losers</h3>

<ul>
	<li>Varonis Systems, Inc. (NASDAQ:<a class="ticker" href="/stock/VRNS#NASDAQ">VRNS</a>) fell 66.1% to $59.50 in pre-market trading.</li>
	<li>Seelos Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/SEEL#NASDAQ">SEEL</a>) fell 12% to $4.18 in pre-market trading. Seelos Therapeutics shares jumped 56% on Friday after BTIG initiated coverage on the stock with a Buy rating and a price target of $14 per share.</li>
	<li>Nova LifeStyle, Inc. (NASDAQ:<a class="ticker" href="/stock/NVFY#NASDAQ">NVFY</a>) fell 11.3% to $4.38 in pre-market trading after surging 10% on Friday.</li>
	<li>Entera Bio Ltd. (NASDAQ:<a class="ticker" href="/stock/ENTX#NASDAQ">ENTX</a>) fell 9.1% to $6.27 in pre-market trading. Entera Bio shares jumped 70% on Friday on continued momentum after the company on March 11th announced its Phase 2 clinical trial of EB613 met its primary endpoint.</li>
	<li>Hepion Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/HEPA#NASDAQ">HEPA</a>) fell 9% to $2.22 in pre-market trading after rising around 5% on Friday.</li>
	<li>Regulus Therapeutics Inc. (NASDAQ:<a class="ticker" href="/stock/RGLS#NASDAQ">RGLS</a>) fell 7.7% to $1.81 in pre-market trading after jumping 17% on Friday. The company, last week, reported a narrower quarterly loss.</li>
	<li>GigaMedia Limited (NASDAQ:<a class="ticker" href="/stock/GIGM#NASDAQ">GIGM</a>) fell 6.8% to $3.80 in pre-market trading after jumping over 15% on Friday.</li>
	<li>Super League Gaming, Inc.(NASDAQ:<a class="ticker" href="/stock/SLGG#NASDAQ">SLGG</a>) fell 5.4% to $6.17 in pre-market trading. Super League Gaming shares fell 5% on Friday after the company reported worse-than-expected Q4 results.</li>
	<li>Express, Inc. (NYSE:<a class="ticker" href="/stock/EXPR#NYSE">EXPR</a>) fell 5.4% to $4.20 in pre-market trading. Express shares jumped around 17% on Friday amid strength in &#39;Reddit stocks&#39; for the session.</li>
	<li>DBV Technologies S.A. (NASDAQ:<a class="ticker" href="/stock/DBVT#NASDAQ">DBVT</a>) fell 5.2% to $5.68 in pre-market trading after surging over 14% on Friday.</li>
</ul>

Penny Stocks

Small Cap

Pre-Market Outlook

32 Stocks Moving in Monday's Pre-Market Session

Today&#39;s 5 Stock Ideas:&nbsp;

<ul>
	<li>CIIG Merger (CIIC)&nbsp;- Shareholders of this special purpose acquisition corporation (SPAC) will vote on its merger with electric vehicle company, Arrival, on Friday, Mar. 19, 2021.</li>
	<li>CrowdStrike (CRWD)&nbsp;- An earnings play for a cybersecurity name. The company will report Q4 earnings on Tuesday after market close.</li>
	<li>Olo, Inc. (OLO)&nbsp;- An IPO play. Shares of this cloud-based software company for on-demand commerce platform for multi-location restaurants are expected to open on Wednesday of this week.</li>
	<li>Solid Biosciences (SLDB)&nbsp;- Expected to release data from a Phase 1/2 study of its Duchenne muscular dystrophy candidate on Thursday of this week.</li>
	<li>MeaTech 3D (MITC)&nbsp;- An IPO from last week. The company develops an industrial process for growing cultured meat combined with 3D printing technology.</li>
</ul>

Benzinga Pro's Top 5 Stocks To Watch For Monday, Mar. 15, 2021: CIIC, CRWD, OLO, SLDB, MITC

<h3>Gainers</h3>

<ul>
	<li>MyMD Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/MYMD#NASDAQ">MYMD</a>) rose 108.2% to $9.16 in pre-market trading after dropping more than 10% on Monday.</li>
	<li>Obalon Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/OBLN#NASDAQ">OBLN</a>) rose 14% to $2.81 in pre-market trading.</li>
	<li>Palatin Technologies, Inc. (NYSE:<a class="ticker" href="/stock/PTN#NYSE">PTN</a>) rose 12.5% to $0.6090 in pre-market trading.</li>
	<li>Sundial Growers Inc. (NASDAQ:<a class="ticker" href="/stock/SNDL#NASDAQ">SNDL</a>) rose 11.7% to $1.05 in pre-market trading after climbing 11% on Monday.</li>
	<li>Meat-Tech 3D Ltd. (NASDAQ:<a class="ticker" href="/stock/MITC#NASDAQ">MITC</a>) rose 10% to $9.17 in pre-market trading. The company, last month, priced its IPO at $10.30 per ADS.</li>
	<li>TDH Holdings, Inc. (NASDAQ:<a class="ticker" href="/stock/PETZ#NASDAQ">PETZ</a>) rose 8.9% to $2.95 in pre-market trading after surging around 28% on Monday.</li>
	<li>Creative Realities, Inc. (NASDAQ:<a class="ticker" href="/stock/CREX#NASDAQ">CREX</a>) shares rose 8.1% to $1.33 in pre-market trading.</li>
	<li>Acasti Pharma Inc. (NASDAQ:<a class="ticker" href="/stock/ACST#NASDAQ">ACST</a>) rose 7.8% to $0.4743 in pre-market trading after adding 8% on Monday.</li>
	<li>Borr Drilling Limited (NYSE:<a class="ticker" href="/stock/BORR#NYSE">BORR</a>) rose 7.6% to $1.04 in pre-market trading.</li>
	<li>22nd Century Group, Inc. (NYSE:<a class="ticker" href="/stock/XXII#NYSE">XXII</a>) rose 7% to $3.80in pre-market trading. 22nd Century Group shares jumped over 10% on Monday following a report Biden is weighing nicotine policy and a ban on menthol cigarettes. The company is engaged in the research and development of modified-risk and potentially less harmful tobacco products.</li>
	<li>Dogness (International) Corporation (NASDAQ:<a class="ticker" href="/stock/DOGZ#NASDAQ">DOGZ</a>) rose 6.7% to $1.76 in pre-market trading.</li>
	<li>ArcLight Clean Transition Corp. (NASDAQ:<a class="ticker" href="/stock/ACTC#NASDAQ">ACTC</a>) shares rose 6% to $15.64 in pre-market trading after declining over 5% on Monday.</li>
	<li>IBM (NYSE:<a class="ticker" href="/stock/IBM#NYSE">IBM</a>) shares rose 3.1% to $137.20 in pre-market trading as the company reported stronger-than-expected results for its first quarter.</li>
</ul>

 
Find out what&#39;s going on in today&#39;s market and bring any questions you have to <a href="http://premarket.benzinga.com/pre-market-show/">Benzinga&#39;s PreMarket Prep</a>.

<a href="https://www.benzinga.com/investing/best-penny-stocks/">Check out these big penny stock gainers and losers</a>

<h3>Losers</h3>

<ul>
	<li>InspireMD, Inc. (NYSE:<a class="ticker" href="/stock/NSPR#NYSE">NSPR</a>) fell 7.5% to $0.4230 in pre-market trading. InspireMD shares climbed over 11% on Monday after the company submitted an application to join the Nasdaq.</li>
	<li>180 Life Sciences Corp. (NASDAQ:<a class="ticker" href="/stock/ATNF#NASDAQ">ATNF</a>) fell 7.3% to $7.72 in pre-market trading after dropping over 16% on Monday.</li>
	<li>Gulf Island Fabrication, Inc. (NASDAQ:<a class="ticker" href="/stock/GIFI#NASDAQ">GIFI</a>) fell 6.7% to $3.64in pre-market trading. Gulf Island Fabrication announced it sold the assets and certain long-term vessel construction contracts of the Shipyard Division to Bollinger Shipyards for approximately $28.6 million.</li>
	<li>Futu Holdings Limited (NASDAQ:<a class="ticker" href="/stock/FUTU#NASDAQ">FUTU</a>) fell 6.7% to $166.15 in pre-market trading. Futu, after the closing bell, announced a common stock offering of 9.5 million ADS.</li>
	<li>Galectin Therapeutics Inc. (NASDAQ:<a class="ticker" href="/stock/GALT#NASDAQ">GALT</a>) fell 5.4% to $2.63 in pre-market trading. Galectin Therapeutics shares climbed 27% on Monday after the company announced neurosurgeon Dr. Ben Carson, Sr. joined the team as a special consultant to accelerate and enhance development of the company&#39;s galectin-3 inhibitor, belapectin.</li>
	<li>Northern Dynasty Minerals Ltd. (NYSE:<a class="ticker" href="/stock/NAK#NYSE">NAK</a>) fell 5.1% to $0.5687 in pre-market trading after jumping over 11% on Monday.</li>
	<li>SOS Limited (NYSE:<a class="ticker" href="/stock/SOS#NYSE">SOS</a>) fell 5.1% to $3.77 in pre-market trading after dropping more than 8% on Monday.</li>
</ul>

20 Stocks Moving in Tuesday's Pre-Market Session

MeaTech 3D Ltd. (NASDAQ:<a class="ticker" href="/stock/MITC#NASDAQ">MITC</a>)&nbsp;(TASE: MITC), a technology company focused on developing cultured meat production capabilities including its proprietary three-dimensional printing technology, biotechnology processes, and customizable manufacturing processes for slaughter-free real meat manufacturing, today announced that its wholly-owned subsidiary, MeaTech Europe, has commenced food technology development activities, with an initial focus on hybrid foods, which are food offerings composed of both plant and cultured fat and/or protein ingredients.

MeaTech 3D Announces Initiation Of Food Technology Development Activities in Europe

<ul>
	<li>As an early-stage company, MeaTech does not currently generate revenues and does not expect to generate any revenue from operations in the near term while it develops its products.</li>
	<li>R&amp;D expenses&nbsp;for 2020 totaled&nbsp;$2.5 million, compared to&nbsp;$0.2 million&nbsp;in 2019, reflecting a rapid expansion of the scope of MeaTech&#39;s research and development abilities.</li>
	<li>Total operating expenses&nbsp;in 2020 reached&nbsp;$18.5 million, compared to&nbsp;$0.4 million&nbsp;in 2019.</li>
	<li>Public listing expenses&nbsp;which did not affect cash flow were recorded in 2020 in the amount of&nbsp;$10.2 million&nbsp;in connection with MeaTech&#39;s reverse merger into a TASE-traded shell company.</li>
	<li>Net loss&nbsp;for 2020 net was&nbsp;$18.5 million, or&nbsp;$0.30&nbsp;per ordinary share, compared to&nbsp;$0.4 million, or&nbsp;$0.02&nbsp;per ordinary share, in 2019. The increase was mainly the result of the public listing expenses and increased operating expenses incurred as MeaTech expanded its cultured meat technology development.</li>
	<li>Cash and equivalents&nbsp;at year-end 2020 increased to&nbsp;$13.5 million, compared to&nbsp;$1.2 million&nbsp;at year-end 2019.
	<ul>
		<li>Total assets&nbsp;increased to&nbsp;$17.4 million&nbsp;at year-end 2020, up from&nbsp;$1.9 million&nbsp;at year-end 2019.M</li>
	</ul>
	</li>
</ul>

Earnings

MeaTech FY 2020 EPS $(0.30) Vs $(0.02) YoY

WIIM

MeaTech 3D shares are trading lower after the company reported FY20 earnings results.

<h3>Gainers</h3>

<ul>
	<li>Cocrystal Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCP#NASDAQ">COCP</a>) shares rose 60.5% to $1.99 in pre-market trading. Cocrystal Pharma recently announced progress on its COVID-19 antiviral drug candidates that target coronaviruses, including SARS-CoV-2, and it also plans to launch a second COVID-19 program with additional antiviral compounds for development, apart from CDI-45205.</li>
	<li>Precipio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPO#NASDAQ">PRPO</a>) rose 40% to $6.93 in pre-market trading. Precipio shares surged 172% on Monday after the company successfully launched its COVID-19 rapid antibody test that tests for both IgG &amp; IgM antibodies.</li>
	<li>Vaxart, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VXRT#NASDAQ">VXRT</a>) rose 22% to $9.79 in pre-market trading after the company said new data obtained from Phase I COVID-19 trial &#39;added to the evidence&#39; suggesting VXA-CoV2-1 shows broad cross-reactivity against other coronaviruses.</li>
	<li>Huttig Building Products, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBP#NASDAQ">HBP</a>) rose 15.8% to $4.85 in pre-market trading after the company swung to a profit in the first quarter.</li>
	<li>51job, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JOBS#NASDAQ">JOBS</a>) shares rose 15.1% to $70.57 in pre-market trading as the company reported the receipt of an updated non-binding proposal to acquire the company for $79.05 per share.</li>
	<li>Gaucho Group Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINO#NASDAQ">VINO</a>) rose 10.4% to $4.34 in pre-market trading after dropping more than 9% in the previous session.</li>
	<li>BioLineRx Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) rose 10% to $3.51 in pre-market trading.</li>
	<li>Renewable Energy Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGI#NASDAQ">REGI</a>) shares rose 8.5% to $57.00 in pre-market trading after reporting strong Q1 results.</li>
	<li>Seanergy Maritime Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHIP#NASDAQ">SHIP</a>) rose 8.2% to $1.32 in pre-market trading after jumping over 10% on Monday.</li>
	<li>LM Funding America, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMFA#NASDAQ">LMFA</a>) rose 8.2% to $1.18 in pre-market trading.</li>
	<li>DBV Technologies S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) rose 7.8% to $6.63 in pre-market trading. The company yesterday reported Q1 results.</li>
	<li>Chegg, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHGG#NYSE">CHGG</a>) rose 3.4% to $85.79 in pre-market trading after the company reported better-than-expected Q1 sales results. The company also announced it raised FY21 sales guidance.</li>
	<li>Elevate Credit, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELVT#NYSE">ELVT</a>) shares rose 3.4% to $3.35 in pre-market trading after the company reported better-than-expected Q1 earnings.</li>
	<li>CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) rose 3% to $80.00 in pre-market trading after the company reported upbeat Q1 results and raised FY21 earnings forecast.</li>
</ul>

 
Find out what&#39;s going on in today&#39;s market and bring any questions you have to <a href="http://premarket.benzinga.com/pre-market-show/">Benzinga&#39;s PreMarket Prep</a>.

<a href="https://www.benzinga.com/investing/best-penny-stocks/">Check out these big penny stock gainers and losers</a>

<h3>Losers</h3>

<ul>
	<li>Image Sensing Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISNS#NASDAQ">ISNS</a>) fell 18.8% to $9.18 in pre-market trading following Q1 results. The company reported a decline in quarterly sales.</li>
	<li>Brooklyn ImmunoTherapeutics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTX#NYSE">BTX</a>) shares fell 17.8% to $64.53 in pre-market trading after jumping over 57% on Monday. On Friday, Brooklyn ImmunoTherapeutics filed a Form 8-K showing that it entered into a purchase agreement with Lincoln Park Capital on Apr. 26 in which the company can sell up to $20 million of common shares to the Chicago-based investment group and asset management firm. Additionally, Nicholas J Singer disclosed that he took a 9%-plus stake in the company in a 13G filing on Friday.</li>
	<li>Barnwell Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRN#NYSE">BRN</a>) fell 13.9% to $2.67 in pre-market trading after jumping around 50% on Monday.</li>
	<li>Ballard Power Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLDP#NASDAQ">BLDP</a>) fell 12.6% to $17.70 in pre-market trading after reporting weak quarterly results.</li>
	<li>Regional Health Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RHE#NYSE">RHE</a>) fell 12% to $12.87 in pre-market trading after surging over 102% on Monday.</li>
	<li>iRobot Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRBT#NASDAQ">IRBT</a>) fell 8.7% to $94.92 in pre-market trading following Q1 results. The company also issued guidance for FY21.</li>
	<li>Maxar Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAXR#NYSE">MAXR</a>) fell 8.2% to $36.00 in pre-market trading after the company swung to a loss in the first quarter.</li>
	<li>Kintara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTRA#NASDAQ">KTRA</a>) fell 7.4% to $1.26 in pre-market trading.</li>
	<li>Meat-Tech 3D Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MITC#NASDAQ">MITC</a>) fell 6.7% to $9.97 in pre-market trading. MeaTech 3D recently initiated process to voluntarily delist its ordinary shares from the Tel Aviv Stock Exchange.</li>
	<li>SmileDirectClub, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDC#NASDAQ">SDC</a>) shares fell 6.3% to $9.96 in pre-market trading after the company reported it sees Q1 EPS of $(0.25), versus the $(0.09) estimate. The company also reported it experienced a systems outage caused by a cybersecurity incident but was able to successfully block the attack.</li>
	<li>Digital Ally, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGLY#NASDAQ">DGLY</a>) fell 5.2% to $1.83 in pre-market trading after gaining more than 7% on Monday.</li>
	<li>The Mosaic Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOS#NYSE">MOS</a>) fell 5% to $33.30 in pre-market trading after the company reported Q1 earnings results.</li>
</ul>

26 Stocks Moving in Tuesday's Pre-Market Session

<h3>Gainers</h3>

<ul>
	<li>Cocrystal Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCP#NASDAQ">COCP</a>) shares jumped 75.4% to $2.1750. Cocrystal Pharma recently announced progress on its COVID-19 antiviral drug candidates that target coronaviruses, including SARS-CoV-2, and it also plans to launch a second COVID-19 program with additional antiviral compounds for development, apart from CDI-45205.</li>
	<li>BioLineRx Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) shares jumped 44.2% to $4.6001 after the company announced positive top-line results from the GENESIS Phase 3 trial evaluating its lead clinical candidate, Motixafortide, in combination with granulocyte colony stimulating factor, the standard-of-care, for hematopoietic stem-cell mobilization for autologous bone marrow transplantation in multiple myeloma patients.</li>
	<li>Shineco, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TYHT#NASDAQ">TYHT</a>) shares climbed 37.9% to $16.47 after the company proposed to acquire 51% equity interests in Mayah Biological Holdings Limited.</li>
	<li>Precipio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPO#NASDAQ">PRPO</a>) gained 27.8% to $6.30. Precipio shares surged 172% on Monday after the company successfully launched its COVID-19 rapid antibody test that tests for both IgG &amp; IgM antibodies.</li>
	<li>Huttig Building Products, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBP#NASDAQ">HBP</a>) jumped 25.5% to $5.26 after the company swung to a profit in the first quarter.</li>
	<li>Neuronetics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STIM#NASDAQ">STIM</a>) surged 18.8% to $12.06 after the company reported Q1 results and raised its FY21 sales guidance.</li>
	<li>Gartner, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IT#NYSE">IT</a>) gained 17.1% to $231.20 after the company reported better-than-expected Q1 results and also said it increased its buyback authorization by $500 million in April.</li>
	<li>Arconic Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARNC#NYSE">ARNC</a>) surged 13.7% to $33.43 after the company reported better-than-expected Q1 results and also raised its FY21 sales guidance.</li>
	<li>51job, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JOBS#NASDAQ">JOBS</a>) shares rose 12.6% to $69.03 as the company reported the receipt of an updated non-binding proposal to acquire the company for $79.05 per share.</li>
	<li>Renewable Energy Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGI#NASDAQ">REGI</a>) shares gained 12.5% to $59.13 after reporting strong Q1 results.</li>
	<li>Vaxart, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VXRT#NASDAQ">VXRT</a>) gained 11% to $8.90 after the company announced at its key opinion leader event that new data obtained from its Phase 1 COVID-19 trial added to the evidence suggesting that VXA-CoV2-1 &mdash; its first COVID-19 oral vaccine construct that triggers mucosal immunity and includes both the S and the N SARS-Cov-2 proteins &mdash; has broad cross-coronavirus activity. The company said its oral vaccine induced higher CD8+ T-Cell responses than those seen with Moderna or Pfizer vaccines in comparative experiments.</li>
	<li>The Bancorp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBBK#NASDAQ">TBBK</a>) surged 10.6% to $24.42 after it was announced the company will join the S&amp;P SmallCap 600.</li>
	<li>SEMrush Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEMR#NYSE">SEMR</a>) jumped 8.7% to $20.88.</li>
	<li>Camping World Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWH#NYSE">CWH</a>) gained 8% to $47.52 after the company reported better-than-expected Q1 results. The company also raised its FY21 adjusted EBITDA guidance.</li>
	<li>Farmer Bros. Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FARM#NASDAQ">FARM</a>) surged 7.5% to $10.75.</li>
	<li>DBV Technologies S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) rose 7.3% to $6.60. The company yesterday reported Q1 results.</li>
	<li>Elevate Credit, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELVT#NYSE">ELVT</a>) shares rose 5% to $3.4011 after the company reported better-than-expected Q1 earnings.</li>
</ul>

 
<a href="https://www.benzinga.com/investing/best-penny-stocks/">Check out these big penny stock gainers and losers</a>

<h3>Losers</h3>

<ul>
	<li>ChemoCentryx, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCXI#NASDAQ">CCXI</a>) fell 39.4% to $29.58. ChemoCentryx, last week, reported a Q1 loss of $0.43 per share.</li>
	<li>Sequential Brands Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SQBG#NASDAQ">SQBG</a>) shares dipped 32.4% to $18.45. Sequential Brands Group&rsquo;s 8-K showed the resignation of Chair William Sweedler.</li>
	<li>Regional Health Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RHE#NYSE">RHE</a>) fell 30.9% to $10.10 after surging over 102% on Monday.</li>
	<li>Brooklyn ImmunoTherapeutics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTX#NYSE">BTX</a>) shares dipped 26% to $58.12 after jumping over 57% on Monday. On Friday, Brooklyn ImmunoTherapeutics filed a Form 8-K showing that it entered into a purchase agreement with Lincoln Park Capital on Apr. 26 in which the company can sell up to $20 million of common shares to the Chicago-based investment group and asset management firm. Additionally, Nicholas J Singer disclosed that he took a 9%-plus stake in the company in a 13G filing on Friday.</li>
	<li>Image Sensing Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISNS#NASDAQ">ISNS</a>) fell 25.3% to $8.45 following Q1 results. The company reported a decline in quarterly sales.</li>
	<li>Barnwell Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRN#NYSE">BRN</a>) fell 22.9% to $2.39 after jumping around 50% on Monday.</li>
	<li>Maxar Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAXR#NYSE">MAXR</a>) fell 22.9% to $30.24 after the company swung to a loss in the first quarter.</li>
	<li>Ballard Power Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLDP#NASDAQ">BLDP</a>) fell 19% to $16.41 after reporting weak quarterly results.</li>
	<li>Ocugen, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCGN#NASDAQ">OCGN</a>) dipped 16.8% to $13.04. Ocugen is expected to report Q1 earnings on Friday, May 7.</li>
	<li>SmileDirectClub, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDC#NASDAQ">SDC</a>) shares fell 15.7% to $8.96 after the company reported it sees Q1 EPS of $(0.25), versus the $(0.09) estimate. The company also reported it experienced a systems outage caused by a cybersecurity incident but was able to successfully block the attack.</li>
	<li>Sabre Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SABR#NASDAQ">SABR</a>) fell 15% to $12.81 following downbeat Q1 results. The company did not offer a business outlook due to the pandemic-induced uncertainty.</li>
	<li>CVR Partners, LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAN#NYSE">UAN</a>) dipped 13.8% to $50.19 after reporting a wider quarterly loss.</li>
	<li>Euroseas Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESEA#NASDAQ">ESEA</a>) fell 13.7% to $15.44.</li>
	<li>Ashford Hospitality Trust, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AHT#NYSE">AHT</a>) dropped 13.6% to $2.9008.</li>
	<li>BioNTech SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) dipped 13.6% to $180.29. The company&#39;s COVID-19 vaccine with Pfizer is expected to get FDA emergency approval for the 12-15 age group next week.</li>
	<li>iRobot Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRBT#NASDAQ">IRBT</a>) fell 12.7% to $90.77 following Q1 results. The company also issued guidance for FY21.</li>
	<li>Top Ships Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOPS#NASDAQ">TOPS</a>) dipped 12.5% to $1.82.</li>
	<li>Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVPH#NASDAQ">RVPH</a>) dropped 12.5% to $5.10.</li>
	<li>Sonoma Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNOA#NASDAQ">SNOA</a>) declined 12% to $8.05.</li>
	<li>Aterian, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATER#NASDAQ">ATER</a>) fell 11.3% to $18.31.</li>
	<li>GBS Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GBS#NASDAQ">GBS</a>) dropped 11.1% to $4.24.</li>
	<li>Seer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEER#NASDAQ">SEER</a>) fell 10.5% to $42.35.</li>
	<li>Bausch Health Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHC#NYSE">BHC</a>) dipped 10.1% to $28.25 after the company reported a wider first-quarter loss of $610 million compared with a loss of $152 million a year earlier, impacted by a $469 million goodwill impairment charge in its Ortho Dermatologics business and a $71-million impairment charge related to a product line in Ortho Dermatologics.</li>
	<li>DMC Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOOM#NASDAQ">BOOM</a>) fell 9.7% to $51.44 after the company announced a proposed public offering of 2.5 million shares of common stock.</li>
	<li>Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) dipped 9.7% to $1.8673. The company recently announced it completed a licensing agreement with New Life Therapeutics.</li>
	<li>Beasley Broadcast Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBGI#NASDAQ">BBGI</a>) dropped 9.5% to $2.55 following Q1 results.</li>
	<li>Meat-Tech 3D Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MITC#NASDAQ">MITC</a>) fell 6.2% to $7.67. MeaTech 3D recently initiated process to voluntarily delist its ordinary shares from the Tel Aviv Stock Exchange.</li>
</ul>

Q1 2021		Est.		Actual		Surprise
EPS		(EXPECTED)2021-06-28
REV		(EXPECTED)2021-06-28

FY 2020		Est.		Actual		Surprise
EPS				-0.300
REV				0

Recent Quotes

Earnings

Related Companies

MeaTech 3D Frequently Asked Questions

How do I buy MeaTech 3D (MITC) stock?

Who are MeaTech 3D's (MITC) competitors?

What is the target price for MeaTech 3D (MITC) stock?

Current Stock Price for MeaTech 3D (MITC)?

Does MeaTech 3D (MITC) pay a dividend?

When is MeaTech 3D (NASDAQ:MITC) reporting earnings?

Is MeaTech 3D (MITC) going to split?

What sector and industry does MeaTech 3D (MITC) operate in?